Tela Bio Financials
TELA Stock | USD 2.94 0.07 2.33% |
Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
---|---|---|---|---|---|---|---|---|---|
Current Ratio | 4.78 | 4.2274 |
|
|
The essential information of the day-to-day investment outlook for Tela Bio includes many different criteria found on its balance sheet. An individual investor should monitor Tela Bio's cash flow, debt, and profitability to accurately make informed decisions on whether to invest in Tela Bio.
Net Income |
|
Tela | Select Account or Indicator |
Understanding current and past Tela Bio Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Tela Bio's financial statements are interrelated, with each one affecting the others. For example, an increase in Tela Bio's assets may result in an increase in income on the income statement.
Please note, the presentation of Tela Bio's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Tela Bio's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Tela Bio's management manipulating its earnings.
Tela Bio Stock Summary
Tela Bio competes with Sight Sciences, Tactile Systems, Clearpoint Neuro, CVRx, and Neuropace. TELA Bio, Inc., a commercial-stage medical technology company, focuses on providing soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patients anatomy. TELA Bio, Inc. was incorporated in 2012 and is headquartered in Malvern, Pennsylvania. Tela Bio operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 123 people.Specialization | Health Care, Health Care Equipment & Services |
Instrument | USA Stock View All |
Exchange | NASDAQ Exchange |
ISIN | US8723811084 |
CUSIP | 872381108 |
Location | Pennsylvania; U.S.A |
Business Address | 1 Great Valley |
Sector | Health Care Equipment & Supplies |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.telabio.com |
Phone | 484 320 2930 |
Currency | USD - US Dollar |
Tela Bio Key Financial Ratios
Return On Equity | -3.42 | ||||
Profit Margin | (0.60) % | ||||
Operating Margin | (0.49) % | ||||
Price To Sales | 1.73 X | ||||
Revenue | 58.45 M |
Tela Bio Key Balance Sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 67.9M | 86.5M | 62.5M | 67.9M | 78.0M | 63.7M | |
Other Current Liab | 3.5M | 6.0M | 8.2M | 10.5M | 14.7M | 8.0M | |
Net Tangible Assets | 28.1M | 46.4M | 17.8M | 11.8M | 13.6M | 14.3M | |
Net Debt | (15.1M) | (43.6M) | (12.4M) | (2.1M) | (5.6M) | (5.9M) | |
Retained Earnings | (167.9M) | (196.7M) | (229.9M) | (274.2M) | (320.9M) | (336.9M) | |
Accounts Payable | 3.2M | 652K | 2.4M | 1.5M | 1.7M | 1.6M | |
Cash | 45.3M | 74.4M | 43.9M | 42.0M | 46.7M | 44.2M | |
Long Term Debt | 30.2M | 30.8M | 31.5M | 39.9M | 40.5M | 32.4M | |
Net Receivables | 2.8M | 2.7M | 4.2M | 6.6M | 9.7M | 10.2M | |
Long Term Debt Total | 31.4M | 30.2M | 31.5M | 39.9M | 45.9M | 30.4M | |
Inventory | 4.6M | 3.9M | 7.7M | 11.8M | 13.2M | 7.4M | |
Other Current Assets | 2.3M | 4.5M | 6.5M | 2.0M | 2.1M | 2.8M | |
Total Liab | 37.0M | 37.4M | 42.4M | 53.6M | 59.2M | 59.2M | |
Net Invested Capital | 61.2M | 79.9M | 51.6M | 54.2M | 59.4M | 62.4M | |
Total Current Assets | 64.3M | 83.2M | 59.1M | 62.4M | 71.7M | 59.5M | |
Net Working Capital | 57.6M | 76.6M | 48.5M | 50.0M | 54.8M | 48.6M | |
Common Stock | 11K | 14K | 15K | 19K | 24K | 15.2K | |
Capital Stock | 11K | 14K | 15K | 19K | 24K | 15.2K | |
Intangible Assets | 2.9M | 2.6M | 2.3M | 2.5M | 2.1M | 2.1M |
Tela Bio Key Income Statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Net Interest Income | (3.6M) | (3.6M) | (3.6M) | (4.1M) | (5.1M) | (5.3M) | |
Interest Expense | 3.6M | 3.6M | 3.6M | 4.1M | 5.2M | 4.1M | |
Total Revenue | 15.4M | 18.2M | 29.5M | 41.4M | 58.5M | 61.4M | |
Gross Profit | 9.3M | 11.2M | 18.8M | 27.0M | 40.1M | 42.1M | |
Operating Income | (19.2M) | (25.3M) | (29.5M) | (39.0M) | (44.1M) | (41.9M) | |
Ebit | (19.2M) | (25.2M) | (29.7M) | (40.2M) | (41.4M) | (43.5M) | |
Research Development | 4.2M | 4.3M | 6.7M | 8.9M | 9.6M | 6.9M | |
Ebitda | (18.8M) | (24.7M) | (29.1M) | (39.1M) | (40.6M) | (42.7M) | |
Cost Of Revenue | 6.2M | 7.0M | 10.7M | 14.4M | 18.3M | 10.0M | |
Income Before Tax | (22.4M) | (28.8M) | (33.3M) | (44.3M) | (46.7M) | (49.0M) | |
Net Income | (25.8M) | (31.9M) | (36.1M) | (44.3M) | (46.7M) | (49.0M) | |
Income Tax Expense | 3.4M | 3.1M | 2.8M | 41K | 640.1K | 608.1K |
Tela Bio Key Cash Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Change To Inventory | (1.8M) | (620K) | (5.2M) | (6.1M) | (2.7M) | (2.9M) | |
Investments | (12.0M) | 9.1M | (627K) | (1.9M) | (1.5M) | (1.5M) | |
Change In Cash | 28.0M | 29.1M | (30.5M) | (1.9M) | 5.0M | 5.2M | |
Free Cash Flow | (28.2M) | (24.6M) | (31.1M) | (42.6M) | (41.5M) | (43.5M) | |
Depreciation | 582K | 525K | 535K | 1.2M | 808K | 645.3K | |
Other Non Cash Items | 2.1M | 1.8M | 2.1M | 4.1M | 1.6M | 2.1M | |
Capital Expenditures | 2.7M | 167K | 627K | 1.9M | 611K | 1.2M | |
Net Income | (22.4M) | (28.8M) | (33.3M) | (44.3M) | (46.7M) | (49.0M) | |
End Period Cash Flow | 45.3M | 74.4M | 43.9M | 42.0M | 47.0M | 44.2M | |
Change To Netincome | 2.6M | 4.0M | 5.8M | 6.9M | 8.0M | 5.1M |
Tela Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Tela Bio's current stock value. Our valuation model uses many indicators to compare Tela Bio value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Tela Bio competition to find correlations between indicators driving Tela Bio's intrinsic value. More Info.Tela Bio is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . At present, Tela Bio's Return On Equity is projected to slightly decrease based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Tela Bio's earnings, one of the primary drivers of an investment's value.Tela Bio Systematic Risk
Tela Bio's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Tela Bio volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Tela Bio correlated with the market. If Beta is less than 0 Tela Bio generally moves in the opposite direction as compared to the market. If Tela Bio Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Tela Bio is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Tela Bio is generally in the same direction as the market. If Beta > 1 Tela Bio moves generally in the same direction as, but more than the movement of the benchmark.
Today, most investors in Tela Bio Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Tela Bio's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Tela Bio growth as a starting point in their analysis.
Price Earnings To Growth Ratio |
|
Tela Bio November 26, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Tela Bio help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Tela Bio. We use our internally-developed statistical techniques to arrive at the intrinsic value of Tela Bio based on widely used predictive technical indicators. In general, we focus on analyzing Tela Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Tela Bio's daily price indicators and compare them against related drivers.
Downside Deviation | 2.83 | |||
Information Ratio | (0) | |||
Maximum Drawdown | 15.4 | |||
Value At Risk | (4.83) | |||
Potential Upside | 6.43 |
Complementary Tools for Tela Stock analysis
When running Tela Bio's price analysis, check to measure Tela Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tela Bio is operating at the current time. Most of Tela Bio's value examination focuses on studying past and present price action to predict the probability of Tela Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tela Bio's price. Additionally, you may evaluate how the addition of Tela Bio to your portfolios can decrease your overall portfolio volatility.
ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
Transaction History View history of all your transactions and understand their impact on performance | |
Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins |